A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Inclusion Criteria

• •1. Subjects who are male or female ≥2 years of age at Screening (Visit 1).
• •2. Subjects who have a diagnosis of AD based on the American Academy of Dermatology AD diagnostic criteria
• •3. Subjects who have had a diagnosis of AD for at least 3 months prior to Screening .
• •4. Subjects who have an IGA of mild or moderate AD Severity and treatable body surface area (BSA) ≥3%at Baseline if not previously enrolled in study MEDI-MM36-301 OR b. IGA ≤ 3, with no minimum BSA and completed through Week 4/EOT Visit 6 of the study MEDI-MM36-301.
• •5. Subject is willing and able to comply with all study-related procedures, including, but not limited to, application of the study drug, and visit requirements.